Open surgical or endovascular revascularization of the lower extremity is not always successful. Early and intermediate-term failures of vascular grafts, stents, and stent grafts occur due to technical mistakes, thrombosis, or intimal hyperplasia. The outcome of lower extremity revascu larization can be improved by adjuvant antithrombotic treatment (antiplatelet drugs, anticoagulation) and by antiproliferative therapy such as drugs, brachytherapy, or gene therapy. Adjuvant drug therapy can be sys temic (oral or parenteral) or local (direct injection or placement of drug-elut ing grafts or stents). Systemic drug therapy may carry the additional benefit of preventing cardiovascular events, such as stroke or myocardial infarction. Unfortunately, it can also be associated with serious, mainly hemorrhagic, adverse effects. We review the English-language literature of antithrombotic and antiproliferative adjuvant therapies in the prevention of early and inter mediate failures following lower extremity revascularizations.
Antithrombotic therapy. In: Current Cardiovascular Drugs20003rd Ed., Editors: Frishman WH, Cheng-Lai A, Chen J.Current Medicine Inc, Philadelphia, pp. 85-119
2.
Green RM, Roedersheimer LR, DeWeese JAEffects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery1982;92:1016-1026
3.
Goldman M., Hall C., Dykes J., Hawker RJ, et al. Does 111 indium-platelet deposition predict patency in prosthetic arterial grafts?Br J Surg1983;70:635-638
4.
Donaldson DR , Salter Mcp, Kester RC, Rajah SM, et al. The influence of platelet inhibition on the patency of femoro-popliteal Dacron bypass graft . Vasc Surg1985; 19:224-230
5.
Kohler TR, Kaufman JL, Kacoyanis G., Clowes A., et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass graft. Surgery1984;96:462-466
6.
McCollum C., Alexander C., Kenchington G., Franks PJ, et al. Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter study. J Vasc Surg1991;13:150-162
7.
Tangelder Mjd , Lawson JA, Algra A., Eikelboom BCSystematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J Vasc Surg1999; 30:701-709
8.
Antiplatelet Trialists' Collaboration. Collaboartive overview of randomized trials of antiplatelet therapy-II: maintenance of vascular graft or arterial patency by antiplatelat therapy. BMJ1994;308:159-168
9.
Heiss HW, Just H., Middleton D., Deichsel G.Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology1990;41: 263-269
10.
Study group on pharmacological treatment after Pta.Platelet inhibition with ASA/Dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial . Eur J Vasc Surg1994;8:83-88
11.
Pompa JJ, Kuntz REPercutaneous coronary and valvular intervention. In: Braunwald E, Zipes, DP, Libby P (eds): Heart Disease: A Textbook of Cardiovascular Medicine, 6th ed., 2001W. B. Saunders Company, pp 1304-1405
12.
Becquemin JPEffects of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. N Engl J Med1997;337:1726-1731
13.
Schomig A., Neumann, F-J., Kastrati A., Schuhlen H., et al. A randomized comparison of antiplatelet and anticoagulant therapy after placement of coronary-artery stents. N Engl J Med1996;334:1084-1089
14.
Leon MB, Baim DS, Popma JJ, Gordon PC, et al. A clinical trial comparing three antithrombotic-drug regimens following coronary artery stenting. N Engl J Med1998;339:1665-1671
15.
Urban P., Macaya C., Rupprecht HJ, Kiemeneij F., et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation1998;98:2126-2132
16.
Bertrand ME , Legrand V., Boland J., Fleck E., et al: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) Study. Circulation1998;98:1597-1603
17.
Anonymous.Effects of perioperative iloprost on patency of femorodistal bypass grafts. The Iloprost Bypass International Study Group. Eur J Vas Endovasc Surg1996;12(3):363-731
18.
George IN, Shattil SIAcquired disorders of platelet function In: Hoffman R, Benz EJ, Shattil ST, Furie B, Cohen, HI, Silberstein LE , McGlave P (eds).: Hematology: Basic Principles and Practice, 3rd ed.2000Churchill Livingstone, Inc., 2172-2186
19.
Rutherford RB, Jones DN, Bergentz SE et al. The efficacy of dextran 40 in preventing early postoperative thrombosis following difficult lower extremity bypass . J Vasc Surg1984;1:765-773
20.
Kretschmer G., Herbst F., Prager M., Sautner T., Wenzl E., Berlakovich GA, Zekert F., Marosi L., Schemper M.A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg1992;127:1112-1115
21.
Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin study): a randomized trial. Lancet2000;355:346-351
22.
Sarac TP, Huber TS, Back MR, Ozaki CK, et al. Warfarin Improves the outcome of infrainguinal vein bypasses grafting at high risk for failureJ Vasc Surg1998;28:446-457
23.
Johnson WC, Williford WO, Members of the Department of Veterans Affairs Cooperative Study #362. Benefits, morbidity and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg2002;35:413-421
24.
Urban P., Buller N., Fox K., et al: Lack of effect of warfarin on the restenosis rate or on clinical outcome after balloon coronary angioplasty. Br Heart J1988;60:485-488
25.
ten Berg JM, Kelder JC, Suttorp MJ, Verheugt FW, et al. Balloon Angioplasty and Anticoagulation Study. A randomized trial assessing the effect of coumarins started before coronary angioplasty on restenosis: results of the 6-month angiographic sub-study of the Balloon Angioplasty and Anticoagulation Study (BAAS). Am Heart J2003;145(1):58-65
26.
Samama CM, Gigou F., Ill P., Enoxart Study group. Low-molecular-weight heparin versus unfractionated heparin in femorodistal reconstructive surgery: a multicenter open randomized study . Ann Vasc Surg1995;9[Suppl]:S45-53
27.
Edmondson RA , Cohen AT, Das SK, Wagner MB, et al. Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet1994;344(8927):914-918
28.
Devine C., McCollum C, North WestFemoro-popliteal Trial Participants. Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass grafting: a multicenter trial. J Vasc Surg2001;33:533-539
29.
Abbott WM, Green RM, Matsumoto T., Wheeler JR, et al. Prosthetic above-knee femoropopliteal bypass grafting: results of a multicenter randomized prospective trial. Above-Knee Femoropopliteal Study Group. J Vasc Surg1997;25(1):19-28
30.
Kiesz RS, Buszman P., Martin JL, Deutsch E., et al. Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study). Circulation2001 ;103(1):26-31
31.
Serruys PW, van Hout B., Bonnier H., Legrand V., et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)Lancet1998;352(9129):673-681
32.
Serruys PW, de Jaegere P., Kiemeneij F., Macaya C., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group . New Engl J Med1994;331 (8):489-495
33.
Nelson SR, deSouza NM, Allison DJEndovascular stents and stent-grafts: is heparin coating desirable ? Cardiovasc Intervent Radiol2000;23(4):252-255
34.
Antiplatelet Trialists' Collaboration.Collaborative overview of randomized trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994 ;308(6921): 81-106
35.
Janzon L., Bergqvist D., Boberg J., Boberg M., et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med1990;227(5):301-308
36.
Anonymus.A randomized, blinded, trial of clopidrogel versus aspirin in patients at risk of ischemic events (CAPRIE). CAPRIE Steering Committee. Lancet1996;348(9038): 1329-1339
Mann MJGene therapy for vein grafts. Curr Cardiol Rep2000;2:29-33
39.
Tamai H., for the TREAT group.Inhibitory effect of tramilast on restenosis after percutaneous transluminal coronary angioplasty (PTCA): A phase III multicenter randomized double blind placebo-controlled trial. J Clin Therap Med1996;2:65-85
40.
Holmes DR Jr , Savage M., LaBlanche JM, Grip L., et al: Results of Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation2002; 106:1243-1250
41.
Costa MA, Sabat M., van der Giessen WJ, Kay IP, et al. Late coronary occlusion after intracoronary brachytherapy. Circulation1999;100(8):789-792.
42.
Minar E., Pokrajac B., Maca T., Ahmadi R., et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation2000;102(22):2694-2699
43.
Wolfram R., Pokrajac B., Ahmadi R., Fellner C., et al. Endovascular brachytherapy for prophylaxis against restenosis after long-segment femoropopliteal stenting: initial results. Radiology2001;220:724-729
44.
Pokrajac B. , Minar E., Kirists C., Potter R.Present status of endovascular brachytherapy in peripheral arteries. Herz2002;27:56-61
45.
Waksman R., Laird JR, Jurkovitz CT, Lansky AJ, et al. Peripheral Artery Radiation Investigational Study (PARIS) Investigators. Intravascular radiation therapy after balloon angioplasty of narrowed femoropopliteal arteries to prevent restenosis: results of the PARIS feasibility clinical trial. J Vasc Interv Radiol2001;12:915-921
46.
Kay IP, Wardeh AJ, Kozuma K., Foley DP, et al. Radioactive stents delay but do not prevent in-stent neointimal hyperplasia. Circulation2001;103:14-17
47.
Marx SO, Marks ARBench to bedside: the development of rapamycin and its application to stent restenosis. Circulation2001;104:852-855
48.
Sousa JE, Costa MA, Abizaid AC, Rensing BJ, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation2001;104:2007-2011
49.
Morice MC, Serruys PW, Sousa JE, Fajadet J., et al for the RAVEL Study Group.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med2002;346:1773-1780
50.
Degertekin M., Serruys PW, Foley DP, Tanabe K., et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation2002; 106: 1610-1613
51.
Sousa JE, Costa MA, Abizaid A., Sousa AG, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation2003;107(1):24-27
52.
Duda SH, Pusich B., Richter G., Landwehr P., et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation2002; 106(12): 1505-1509
53.
Hiatt BL, Ikeno F., Yeung AC, Carter AJDrug-eluting stents for the prevention of restenosis: in quest for the Holy Grail. Catheter Cardiovasc Interven2002;55: 409-417
54.
Oberhoff M. , Herdeg C., Baumbach A., Karsch KRStent-based antirestenotic coatings (sirolimus/paclitaxel) . Catheter Cardiovasc Interven2002;55:404-408
55.
Grube E., Silber S., Hauptmann KE, Mueller R., et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions . Circulation2003;107(1):38-42
56.
Liistro F., Stankovic G., Di Mario C., Takagi T., et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation2002; 105(16):1883-1886
57.
Virmani R., Liistro F., Stankovic G., Di Mario C., et al. Mechanism of late in-stent. restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation2002;106(21):2649-2651
58.
Kullo IJ, Mozes G., Schwartz RS, Gloviczki P., et al. Adventitial gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries alters vascular reactivity. Circulation1996;7:2254-2261
59.
Kullo IJ, Mozes G., Schwartz RS, Gloviczki P., et al. Enhanced endothelium-dependent relaxation after gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries . Hypertension1997;30:314-320
60.
Mozes G., Gloviczki P., Menawat SS, Kullo IJ, et al. Adenoviral-mediated gene transfer of macrophage colony stimulating factor to the arterial wall in vivo. Arterioscler Thromb Vasc Biol1998;7:1157-1163
61.
Khurana R., Martin JF, Zachary I.Gene therapy for cardiovascular disease: a case for cautious optimism . Hypertension2001;38:1210-1216
62.
Rajagopalan S., Shah M., Luciano A., Crystal R., et al. Adenovirus-mediated gene transfer of VEGF (121) improves lower-extremity endothelial function and flow reserve . Circulation2001;104(7):753-755
63.
Symes JF, Losordo DW, Vale PRGene therapy with vascular endothelial growth factor for inoperable coronary disease. Ann Thorac Surg1999;68:830-837
64.
Schumacher B., Pecher P., von Specht BU, StegmannT. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation1998;97:645-650
65.
Henry TD, Annex BH, Azrin MA, McKendall GR, et al. Final results of VIVA trial of the rhVEGF human therapeutic angiogenesis. Circulation1999;100:I-476
66.
Mann MJ, Whittemore AD, Donaldson MC, Belkin M., et al. Ex vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomized, controlled trial. Lancet1999;354:1493-1498
